Citadel Advisors
CTXR icon

Citadel Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Citadel Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,900
Closed -$13.5K – 12844
2025
Q3 		$13.5K Sell
10,900
-14,800
-58% -$20.6K ﹤0.01% 12546
2025
Q2 		$40.9K Buy
25,700
+15,900
+162% +$14.6K ﹤0.01% 11870
2025
Q1 		$14.6K Sell
9,800
-15,840
-62% -$37.9K ﹤0.01% 13353
2024
Q4 		$103K Buy
25,640
+24,356
+1,897% +$164K ﹤0.01% 11445
2024
Q3 		$16.1K Buy
+1,284
New +$21.6K ﹤0.01% 12944
2024
Q1 		– Sell
-716
Closed -$13.5K – 14672
2023
Q4 		$13.5K Sell
716
-4
-0.6% -$76 ﹤0.01% 12924
2023
Q3 		$12.3K Sell
720
-16
-2% -$380 ﹤0.01% 12972
2023
Q2 		$22.1K Sell
736
-296
-29% -$9.74K ﹤0.01% 12640
2023
Q1 		$30.2K Sell
1,032
-32
-3% -$922 ﹤0.01% 12735
2022
Q4 		$21K Buy
1,064
+28
+3% +$764 ﹤0.01% 13111
2022
Q3 		$31K Buy
1,036
+24
+2% +$660 ﹤0.01% 11890
2022
Q2 		$23K Sell
1,012
-16
-2% -$439 ﹤0.01% 12346
2022
Q1 		$46K Sell
1,028
-588
-36% -$23.2K ﹤0.01% 12843
2021
Q4 		$62K Sell
1,616
-748
-32% -$33.9K ﹤0.01% 13118
2021
Q3 		$120K Buy
+2,364
New +$119K ﹤0.01% 12644

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors's CTXR Position: Q1 2025 in Review

Citadel Advisors sold out of Citius Pharmaceuticals (CTXR) in Q1 2025, closing a stake of 1 share — an estimated $2 sold.

Citadel Advisors first reported a position in CTXR in Q1 2019 and held it in 17 quarters. The position peaked at $728K in Q2 2021. 28 funds tracked by Wall St. Rank hold CTXR as of Q1 2025.

  • Citadel Advisors reported no remaining Citius Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 1 Citius Pharmaceuticals share in Q1 2025, an estimated $2.
  • Citadel Advisors first reported a position in Citius Pharmaceuticals in Q1 2019 and held it in 17 quarters.
  • Citadel Advisors's Citius Pharmaceuticals position peaked at $728K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.